Business Standard

Dr Reddy's Lab rises 2.3%

Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Quick Links

 

Market News

Business as usual resumes for markets

Economists do not expect the referendum result to impact economic data flow

Yahoo rakes in another jackpot from Alibaba's IPO

Yahoo is in line to make anywhere from $8.3 billion to $9.5 billion from the initial public offering

India Vix touches all-time low of 11.88

This indicates that investors remain optimistic that the market will continue to trend upward

MCX-SX to approach CCI against rival BSE

Low transaction fees in BSE's currency derivative segment anti-competitive, alleges MCX-SX

PFRDA sets up an expert committee to assess investment guidelines

The panel will review current investment guidelines for NPS schemes for private sector and recommend changes or new schemes

Back to Top